Patent · US Active

Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl- D3)pyridazine-3-carboxamide

US11649226B2 · kind B2 · utility

0Cited by

3References

2Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Bahar Inankur · New Brunswick, US
Sergei Kolotuchin · Princeton, US
Maxime C. Soumeillant · Hamilton Square, US
Daniel S. Treitler · Cranford, US

Key dates

Filing date	Dec 22, 2020
Grant date	May 16, 2023
Priority date	—
Expiry date	Dec 22, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula:Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.